Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05135559CT.gov A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors | — | Active Not Recruiting | — | — | — |
NCT04921956CT.gov Compassionate Use of Concizumab if You Have Haemophilia | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Concizumab (this asset) | Novo Nordisk A/S | P3 | B · 60 |
| Antihemophilic Factor, Human Recombinant | Chulalongkorn University | P4 | BB |
| Stsp-0601 For | Jiangsu BioJeTay Biotechnology Co., Ltd. | P3 | BB |
| Immunoglobulin G1, Anti-(Human Tissue Factor Pathway Inhibitor) (Human Monoclonal Pf-06741086 .Gamma.1-Chain), Disulfide With Human Monoclonal Pf-06741086 .Lambda.-Chain, Dimer | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Factor Viii Inhibitor Bypassing Fraction | Baxalta now part of Shire | P3 | BB |
| Ribavirin | Kenneth Sherman | P4 | BB |
| Pegyinterferon-Alfa-2A | Baqiyatallah Medical Sciences University | P4 | BB |
| Eptacog Alfa (Activated) | Laboratoire français de Fractionnement et de Biotechnologies | P3 | BB |
| Efanesoctocog Alfa | Swedish Orphan Biovitrum | P4 | BB |
+24 more in the Hemophilia cohort
Other indications for Concizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia A | — | P3 | BB · 68 |
| Hemophilia B | — | P3 | BB · 66 |
| Inherited Blood Coagulation Disorder | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Antihemophilic Factor, Human RecombinantChulalongkorn UniversityBB
- Stsp-0601 ForJiangsu BioJeTay Biotechnology Co., Ltd.BB
- Immunoglobulin G1, Anti-(Human Tissue Factor Pathway Inhibitor) (Human Monoclonal Pf-06741086 .Gamma.1-Chain), Disulfide With Human Monoclonal Pf-06741086 .Lambda.-Chain, DimerInstitute of Hematology & Blood Diseases Hospital, ChinaBB
- Factor Viii Inhibitor Bypassing FractionBaxalta now part of ShireBB
- RibavirinKenneth ShermanBB
Citation
Floatz Terminal. Concizumab in Hemophilia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/concizumab-hemophilia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →